全文获取类型
收费全文 | 47105篇 |
免费 | 3244篇 |
国内免费 | 17篇 |
专业分类
50366篇 |
出版年
2023年 | 262篇 |
2022年 | 625篇 |
2021年 | 1119篇 |
2020年 | 627篇 |
2019年 | 819篇 |
2018年 | 1116篇 |
2017年 | 941篇 |
2016年 | 1603篇 |
2015年 | 2446篇 |
2014年 | 2627篇 |
2013年 | 3463篇 |
2012年 | 4091篇 |
2011年 | 3902篇 |
2010年 | 2401篇 |
2009年 | 2093篇 |
2008年 | 2937篇 |
2007年 | 2870篇 |
2006年 | 2580篇 |
2005年 | 2372篇 |
2004年 | 2222篇 |
2003年 | 2131篇 |
2002年 | 1938篇 |
2001年 | 378篇 |
2000年 | 259篇 |
1999年 | 398篇 |
1998年 | 489篇 |
1997年 | 324篇 |
1996年 | 306篇 |
1995年 | 290篇 |
1994年 | 270篇 |
1993年 | 270篇 |
1992年 | 175篇 |
1991年 | 175篇 |
1990年 | 187篇 |
1989年 | 135篇 |
1988年 | 128篇 |
1987年 | 109篇 |
1986年 | 87篇 |
1985年 | 110篇 |
1984年 | 113篇 |
1983年 | 83篇 |
1982年 | 94篇 |
1981年 | 92篇 |
1980年 | 82篇 |
1979年 | 77篇 |
1978年 | 45篇 |
1977年 | 53篇 |
1976年 | 39篇 |
1975年 | 40篇 |
1973年 | 42篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Laura
iburc Marius Bembea Dana Carmen Zaha Alexandru Daniel Jurca Cosmin Mihai Vesa Ioana Adela Raiu Claudia Maria Jurca 《Current issues in molecular biology》2022,44(5):1851
IL-17 inhibitors (IL-17i) are medicines used to treat dermatological and rheumatic diseases They belong to a class of medicines called biological disease-modifying anti-rheumatic drugs (bDMARDs). This class of drugs has had a major impact on the therapy of autoimmune diseases, being much safer and more effective than treatment with small molecules. At the same time, they have highly beneficial effects on skin and joint changes, and their efficacy has been extensively monitored and demonstrated in numerous clinical trials. More and more such drugs are still being discovered today to ensure the best possible treatment of these patients, but more frequently and relatively constantly three agents are used. Two of them (Secukinumab and Ixekizumab) inhibit IL-17A directly, and the third, Brodamulab, inhibits the IL-17A receptor. Although they are extremely effective in the treatment of these diseases, sometimes their administration has been associated with paradoxical effects, i.e., there is an exacerbation of the inflammatory process. Tough, clinical trials of IL-17i have described cases of exacerbation or even onset of inflammatory bowel disease (IBD), such as Crohn’s disease and ulcerative colitis, after administration of these drugs in patients previously diagnosed with psoriasis (PS), psoriatic arthritis (PsA), or ankylosing spondylitis (AS). The pathophysiological mechanism of action is not well understood at present. One explanation would be that this hyperreactive inflammatory process would be triggered by Interferon 1 derived from dendritic plasma cells. Even though there are many reports in the recent literature about the role of IL17i in the onset of IBD, conclusions of studies do not converge. Some of them show an increased incidence of IBD in patients treated with IL17i, while some others affirm their safety of them. In the near future we will surely have more data emerging from ongoing meta-analyses regarding safety of use IL17i in patients who are at risk of developing IBD. Clinical and paraclinical evaluation (inflammatory intestinal markers) are carefully advised before recommending treatment with IL-17i and after initiation of treatment, and prospective surveillance by clinical and biomarkers of patients treated with IL-17i is absolutely essential to capture the onset of IBD. 相似文献
102.
Marek Zubrzycki Maria Zubrzycka Grzegorz Wysiadecki Janusz Szemraj Hanna Jerczynska Mariusz Stasiolek 《Current issues in molecular biology》2022,44(5):2401
The endocannabinoid system (ECS) plays an important role in pain processing and modulation. Since the specific effects of endocannabinoids within the orofacial area are largely unknown, we aimed to determine whether an increase in the endocannabinoid concentration in the cerebrospinal fluid (CSF) caused by the peripheral administration of the FAAH inhibitor URB597 and tooth pulp stimulation would affect the transmission of impulses between the sensory and motor centers localized in the vicinity of the third and fourth cerebral ventricles. The study objectives were evaluated on rats using a method that allowed the recording of the amplitude of evoked tongue jerks (ETJ) in response to noxious tooth pulp stimulation and URB597 treatment. The amplitude of ETJ was a measure of the effect of endocannabinoids on the neural structures. The concentrations of the endocannabinoids tested (AEA and 2-AG) were determined in the CSF, along with the expression of the cannabinoid receptors (CB1 and CB2) in the tissues of the mesencephalon, thalamus, and hypothalamus. We demonstrated that anandamide (AEA), but not 2-arachidonoylglycerol (2-AG), was significantly increased in the CSF after treatment with a FAAH inhibitor, while tooth pulp stimulation had no effect on the AEA and 2-AG concentrations in the CSF. We also found positive correlations between the CSF AEA concentration and cannabinoid receptor type 1 (CB1R) expression in the brain, and between 2-AG and cannabinoid receptor type 2 (CB2R), and negative correlations between the CSF concentration of AEA and brain CB2R expression, and between 2-AG and CB1R. Our study shows that endogenous AEA, which diffuses through the cerebroventricular ependyma into CSF and exerts a modulatory effect mediated by CB1Rs, alters the properties of neurons in the trigeminal sensory nuclei, interneurons, and motoneurons of the hypoglossal nerve. In addition, our findings may be consistent with the emerging concept that AEA and 2-AG have different regulatory mechanisms because they are involved differently in orofacial pain. We also suggest that FAAH inhibition may offer a therapeutic approach to the treatment of orofacial pain. 相似文献
103.
Nicola Pirastu Ciara McDonnell Eryk J. Grzeszkowiak Ninon Mounier Fumiaki Imamura Jordi Merino Felix R. Day Jie Zheng Nele Taba Maria Pina Concas Linda Repetto Katherine A. Kentistou Antonietta Robino Tnu Esko Peter K. Joshi Krista Fischer Ken K. Ong Tom R. Gaunt Zoltn Kutalik John R. B. Perry James F. Wilson 《PLoS genetics》2022,18(6)
Diet is considered as one of the most important modifiable factors influencing human health, but efforts to identify foods or dietary patterns associated with health outcomes often suffer from biases, confounding, and reverse causation. Applying Mendelian randomization in this context may provide evidence to strengthen causality in nutrition research. To this end, we first identified 283 genetic markers associated with dietary intake in 445,779 UK Biobank participants. We then converted these associations into direct genetic effects on food exposures by adjusting them for effects mediated via other traits. The SNPs which did not show evidence of mediation were then used for MR, assessing the association between genetically predicted food choices and other risk factors, health outcomes. We show that using all associated SNPs without omitting those which show evidence of mediation, leads to biases in downstream analyses (genetic correlations, causal inference), similar to those present in observational studies. However, MR analyses using SNPs which have only a direct effect on the exposure on food exposures provided unequivocal evidence of causal associations between specific eating patterns and obesity, blood lipid status, and several other risk factors and health outcomes. 相似文献
104.
105.
Ruth Falkenberg Maximilian Fochler Lisa Sigl Hermann Bürstmayr Stephanie Eichorst Sebastian Michel Eva Oburger Christiana Staudinger Barbara Steiner Dagmar Woebken 《EMBO reports》2022,23(7)
Research needs a balance of risk‐taking in “breakthrough projects” and gradual progress. For building a sustainable knowledge base, it is indispensable to provide support for both. Subject Categories: Careers, Economics, Law & Politics, Science Policy & PublishingScience is about venturing into the unknown to find unexpected insights and establish new knowledge. Increasingly, academic institutions and funding agencies such as the European Research Council (ERC) explicitly encourage and support scientists to foster risky and hopefully ground‐breaking research. Such incentives are important and have been greatly appreciated by the scientific community. However, the success of the ERC has had its downsides, as other actors in the funding ecosystem have adopted the ERC’s focus on “breakthrough science” and respective notions of scientific excellence. We argue that these tendencies are concerning since disruptive breakthrough innovation is not the only form of innovation in research. While continuous, gradual innovation is often taken for granted, it could become endangered in a research and funding ecosystem that places ever higher value on breakthrough science. This is problematic since, paradoxically, breakthrough potential in science builds on gradual innovation. If the value of gradual innovation is not better recognized, the potential for breakthrough innovation may well be stifled.
While continuous, gradual innovation is often taken for granted, it could become endangered in a research and funding ecosystem that places ever higher value on breakthrough science.Concerns that the hypercompetitive dynamics of the current scientific system may impede rather than spur innovative research have been voiced for many years (Alberts et al, 2014). As performance indicators continue to play a central role for promotions and grants, researchers are under pressure to publish extensively, quickly, and preferably in high‐ranking journals (Burrows, 2012). These dynamics increase the risk of mental health issues among scientists (Jaremka et al, 2020), dis‐incentivise relevant and important work (Benedictus et al, 2016), decrease the quality of scientific papers (Sarewitz, 2016) and induce conservative and short‐term thinking rather than risk‐taking and original thinking required for scientific innovation (Alberts et al, 2014; Fochler et al, 2016). Against this background, strong incentives for fostering innovative and daring research are indispensable. 相似文献
106.
Harshad S. Ugamraj Kevin Dang Laure-Hlne Ouisse Benjamin Buelow Eduardo N. Chini Giulia Castello James Allison Starlynn C Clarke Laura M. Davison Roland Buelow Rong Deng Suhasini Iyer Ute Schellenberger Sankar N. Manika Shipra Bijpuria Astrid Musnier Anne Poupon Maria Cristina Cuturi Wim van Schooten Pranjali Dalvi 《MABS-AUSTIN》2022,14(1)
107.
108.
Paula Martínez Raúl Snchez-Vzquez Iole Ferrara-Romeo Rosa Serrano Juana M. Flores Maria A. Blasco 《PLoS genetics》2022,18(6)
The shelterin protein POT1 has been found mutated in many different familial and sporadic cancers, however, no mouse models to understand the pathobiology of these mutations have been developed so far. To address the molecular mechanisms underlying the tumorigenic effects of POT1 mutant proteins in humans, we have generated a mouse model for the human POT1R117C mutation found in Li-Fraumeni-Like families with cases of cardiac angiosarcoma by introducing this mutation in the Pot1a endogenous locus, knock-in for Pot1aR117C. We find here that both mouse embryonic fibroblasts (MEFs) and tissues from Pot1a+/ki mice show longer telomeres than wild-type controls. Longer telomeres in Pot1a+/ki MEFs are dependent on telomerase activity as they are not found in double mutant Pot1a+/ki Tert-/- telomerase-deficient MEFs. By using complementation assays we further show that POT1a pR117C exerts dominant-negative effects at telomeres. As in human Li-Fraumeni patients, heterozygous Pot1a+/ki mice spontaneously develop a high incidence of angiosarcomas, including cardiac angiosarcomas, and this is associated to the presence of abnormally long telomeres in endothelial cells as well as in the tumors. The Pot1a+/R117C mouse model constitutes a useful tool to understand human cancers initiated by POT1 mutations. 相似文献
109.
110.
Mustapha Arkoun Laëtitia Jannin Philippe Laîné Philippe Etienne Céline Masclaux-Daubresse Sylvie Citerne Maria Garnica José-Maria Garcia-Mina Jean-Claude Yvin Alain Ourry 《Plant and Soil》2013,362(1-2):79-92